J
Joshua Cohen
Researcher at Tufts Center for the Study of Drug Development
Publications - 65
Citations - 990
Joshua Cohen is an academic researcher from Tufts Center for the Study of Drug Development. The author has contributed to research in topics: Reimbursement & Health care. The author has an hindex of 19, co-authored 63 publications receiving 927 citations. Previous affiliations of Joshua Cohen include Tufts University & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Clinical and economic challenges facing pharmacogenomics
TL;DR: Clinical, regulatory and reimbursement issues with respect to eight, high profile personalized medicines and their companion diagnostics are reviewed, and Medicare parts B and D reimbursement of the eight drugs are determined from publicly available databases.
Journal ArticleDOI
Switching prescription drugs to over the counter
TL;DR: The roles that pharmaceutical firms, healthcare organisations, and government regulatory agencies played in three recent switches that have fuelled global debate are illustrated: simvastatin in theUnited Kingdom, omeprazole in Sweden, and loratadine in the United States are illustrated.
Journal ArticleDOI
Patient access to pharmaceuticals: an international comparison
TL;DR: The study confirms the frequently cited problems of access in European countries: lag between marketing approval and reimbursement, and inflexibility in respect of the extent to which beneficiaries control their choice of drug benefit.
Journal ArticleDOI
Are payers treating orphan drugs differently
Joshua Cohen,Abigail Felix +1 more
TL;DR: Examining payer coverage in the United States, England and Wales, and the Netherlands of outpatient orphan drugs approved between 1983 and 2012, as well as the 11 most expensive orphan drugs, found that orphan drugs have more coverage restrictions than non-orphan drugs in all three jurisdictions.
Journal ArticleDOI
The increasingly complex fourth hurdle for pharmaceuticals
TL;DR: Although drugs that are cost effective may lead to unambiguous health gains among patient groups for whom the drugs are indicated, the opportunity costs could conceivably lead to a reduction in aggregate health gains, or failure to meet different kinds of equity considerations.